Cream or foam in pedal skin care: Towards the ideal vehicle for urea used against dry skin

International Journal of Cosmetic Science

Volumn 33, Issue 1, 2011, Pages 37-43

  Borelli, C ^a   Bielfeldt, S ^b   Borelli, S ^c   Schaller, M ^d   Korting, H C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ProDERM Institut für Angewandte Dermatologische Forschung GmbH   (Germany)

^c Dermatologisches Ambulatorium   (Switzerland)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

cream foam; pedal skin; skincare; transepidermal water loss (TEWL)

Indexed keywords

ALLPRESAN; COSMETIC; DRUG VEHICLE; GEHWOL; PETROLATUM; UNCLASSIFIED DRUG; UREA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREAM; DIABETIC PATIENT; DRUG EFFICACY; DRY SKIN; FEMALE; FOAM; FOOT CARE; FOREARM; HUMAN; HUMIDIFIER; INSULIN DEPENDENT DIABETES MELLITUS; MOISTURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN CARE; SKIN WATER LOSS; SKINFOLD THICKNESS; STRATUM CORNEUM; VOLUNTEER;

DERMATOLOGIC AGENTS; FEMALE; FOOT; HUMANS; MIDDLE AGED; PHARMACEUTICAL VEHICLES; UREA;

EID: 78449280376     PISSN: 01425463     EISSN: 14682494     Source Type: Journal    
DOI: 10.1111/j.1468-2494.2010.00576.x     Document Type: Article

References (32)

1. Elias, P.M., The skin barrier as an innate immune element. Semin. Immunopathol. 29, 3-14 (2007).
2. Bouwstra, J.A., and, Ponec, M., The skin barrier in healthy and diseased state. Biochim. Biophys. Acta 1758, 2080-2095 (2006).
3. Buraczewska, I., Brostrom, U., and, Loden, M., Artificial reduction in transepidermal water loss improves skin barrier function. Br. J. Dermatol. 157, 82-86 (2007).
4. Rawlings, A.V., and, Harding, C.R., Moisturization and skin barrier function. Dermatol. Ther. 17 (Suppl. 1), 43-48 (2004).
5. Proksch, E., The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol. Physiol. 21, 75-80 (2008).
6. Proksch, E., and, Lachapelle, J.M., The management of dry skin with topical emollients-recent perspectives. J. Dtsch. Dermatol. Ges. 3, 768-774 (2005).
7. Fluhr, J.W., Miteva, M., Primavera, G., Ziemer, M., Elsner, P., and, Berardesca, E., Functional assessment of a skin care system in patients on chemotherapy. Skin Pharmacol. Physiol. 20, 253-259 (2007).
8. Pavicic, T., and, Korting, H.C., Xerosis and callus formation as a key to the diabetic foot syndrome: dermatologic view of the problem and its management. J. Dtsch. Dermatol. Ges. 4, 935-941 (2006).
9. Foster, A., An evaluation of NICE guidelines on foot care for patients with diabetes. Nurs. Times 100, 52-53 (2004).
10. Welzel, J., Wilhelm, K.P., and, Wolff, H.H., Skin permeability barrier and occlusion: no delay of repair in irritated human skin. Contact Derm. 35, 163-168 (1996).
11. Ademola, J., Frazier, C., Kim, S.J., Theaux, C., and, Saudez, X., Clinical evaluation of 40% urea and 12% ammonium lactate in the treatment of xerosis. Am. J. Clin. Dermatol. 3, 217-222 (2002).
12. Kuster, W., Bohnsack, K., Rippke, F., Upmeyer, H.J., Groll, S., and, Traupe, H., Efficacy of urea therapy in children with ichthyosis. A multicenter randomized, placebo-controlled, double-blind, semilateral study. Dermatology 196, 217-222 (1998).
13. Serup, J., A double-blind comparison of two creams containing urea as the active ingredient. Assessment of efficacy and side-effects by non-invasive techniques and a clinical scoring scheme. Acta Derm. Venereol. Suppl. (Stockh.) 177, 34-43 (1992).
14. Wohlrab, W., [Significance of urea in external therapy]. Hautarzt 40 (Suppl. 9), 35-41 (1989).
15. Heinrich, U., Koop, U., Jeneveu- Duchemin, M.-C., et al. Multicentre comparison of skin hydratation in terms of physical-, physiological- and product-dependent parametersby the capacitive method (corneometer CM 825). Int. J. Cosmet. Sci. 25, 45-53 (2003).
16. Verdier-Sevrain, S., and, Bonte, F., Skin hydration: a review on its molecular mechanisms. J. Cosmet. Dermatol. 6, 75-82 (2007).
17. Stamatas, G.N., de Sterke, J., Hauser, M., von Stetten, O., and, van der Pol, A., Lipid uptake and skin occlusion following topical application of oils on adult and infant skin. J. Dermatol. Sci. 50, 135-142 (2008).
18. Marques, J.P., Basso, D.S., and, Nunes, A.S., A new technique associated with the evaporimetry method for evaluating occlusion. Int. J. Cosmet. Sci. 29, 97-102 (2007).
19. Ceschel, G.C., Maffei, P., Porzio, S., et al. In vitro permeation screening of a new formulation of thiocolchicoside containing various enhancers. Drug Deliv. 9, 259-263 (2002).
20. Tamarkin, D., Friedman, D., and, Shemer, A., Emollient foam in topical drug delivery. Expert. Opin. Drug Deliv. 3, 799-807 (2006).
21. Franz, T.J., Parsell, D.A., Halualani, R.M., Hannigan, J.F., Kalbach, J.P., and, Harkonen, W.S., Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int. J. Dermatol. 38, 628-632 (1999).
22. Housman, T.S., Mellen, B.G., Rapp, S.R., Fleischer, A.B. Jr, and, Feldman, S.R., Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis 70, 327-332 (2002).
23. Pinnagoda, J., Tupker, R.A., Agner, T., and, Serup, J., Guidelines for transepidermal water loss (TEWL) measurement. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Derm. 22, 164-178 (1990).
24. Serup, J., TEWL measurement standardization. Acta Derm. Venereol. 75, 91-92 (1995).
25. Franz, T.J., Lehman, P.A., Feldman, S.R., and, Spellman, M.C., Bioavailability of clobetasol propionate in different vehicles. Skin Pharmacol. Appl. Skin Physiol. 16, 212-216 (2003).
26. Frosch, P.J., Schulze-Dirks, A., Hoffmann, M., and, Axthelm, I., Efficacy of skin barrier creams (II). Ineffectiveness of a popular "skin protector" against various irritants in the repetitive irritation test in the guinea pig. Contact Derm. 29, 74-77 (1993).
27. Hughes, J., and, Rustin, M., Corticosteroids. Clin. Dermatol. 15, 715-721 (1997).
28. Feldman, S.R., Sangha, N., and, Setaluri, V., Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles. J. Am. Acad. Dermatol. 42, 1017-1020 (2000).
29. Fowler Jr, J.F., Efficacy of a skin-protective foam in the treatment of chronic hand dermatitis. Am. J. Contact Dermat. 11, 165-169 (2000).
30. Melian, E.B., Spencer, C.M., and, Jarvis, B., Clobetasol propionate foam, 0.05%. Am. J. Clin. Dermatol. 2, 89-92 (2001).
31. Woodford, R., and, Barry, B.W., Bioavailability and activity of topical corticosteroids from a novel drug delivery system, the aerosol quick-break foam. J. Pharm. Sci. 66, 99-103 (1977).
32. Huang, X., Tanojo, H., Lenn, J., Deng, C.H., and, Krochmal, L., A novel foam vehicle for delivery of topical corticosteroids. J. Am. Acad. Dermatol. 53, S26-S38 (2005).